"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Recent industry developments such as mergers & acquisitions
4.2 Regulatory scenario for key countries
4.3 Prevalence of Key Retinal Diseases, in Major Countries
4.4 Pipeline Analysis
4.5 Patent Snapshot
5. Global Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2 Market Analysis, Insights and Forecast – By Disease Indication
5.2.1 Macular Degeneration
5.2.2 Diabetic Macular Edema
5.2.3 Diabetic Retinopathy
5.2.4 Retinal Vein Occlusion
5.2.5 Others
5.3. Market Analysis, Insights and Forecast – By End User
5.3.1 Hospital Pharmacy
5.3.2 Retail Pharmacy
5.3.3 Others
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1 North America
5.4.2 Europe
5.4.3 Asia Pacific
5.4.4 Latin America
5.4.5 Middle East & Africa
6. North America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Disease Indication
6.2.1 Macular Degeneration
6.2.2 Diabetic Macular Edema
6.2.3 Diabetic Retinopathy
6.2.4 Retinal Vein Occlusion
6.2.5 Others
6.3. Market Analysis – By End User
6.3.1 Hospital Pharmacy
6.3.2 Retail Pharmacy
6.3.3 Others
6.4. Market Analysis – By Country
6.4.1 U.S.
6.4.2 Canada
7. Europe Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Disease Indication
7.2.1 Macular Degeneration
7.2.2 Diabetic Macular Edema
7.2.3 Diabetic Retinopathy
7.2.4 Retinal Vein Occlusion
7.2.5 Others
7.3. Market Analysis – By End User
7.3.1 Hospital Pharmacy
7.3.2 Retail Pharmacy
7.3.3 Others
7.4. Market Analysis – By Country
7.4.1 Germany
7.4.2 U.K.
7.4.3 France
7.4.4 Italy
7.4.5 Spain
7.4.6 Scandinavia
7.4.7 Rest of Europe
8. Asia Pacific Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Disease Indication
8.2.1 Macular Degeneration
8.2.2 Diabetic Macular Edema
8.2.3 Diabetic Retinopathy
8.2.4 Retinal Vein Occlusion
8.2.5 Others
8.3. Market Analysis – By End User
8.3.1 Hospital Pharmacy
8.3.2 Retail Pharmacy
8.3.3 Others
8.4. Market Analysis – By Country
8.4.1 India
8.4.2 China
8.4.3 Japan
8.4.4 Australia
8.4.5 Southeast Asia
8.4.6 Rest of Asia Pacific
9. Latin America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis – By Type
9.2.1 Macular Degeneration
9.2.2 Diabetic Macular Edema
9.2.3 Diabetic Retinopathy
9.2.4 Retinal Vein Occlusion
9.2.5 Others
9.3. Market Analysis – By End User
9.3.1 Hospital Pharmacy
9.3.2 Retail Pharmacy
9.3.3 Others
9.4. Market Analysis – By Country
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Rest of Latin America
10. Middle East &Africa Retinal Disease Therapeutics Market Analysis, Insights and Forecast,2015-2026
10.1. Key Findings / Summary
10.2. Market Analysis – By Disease Indication
10.2.1 Macular Degeneration
10.2.2 Diabetic Macular Edema
10.2.3 Diabetic Retinopathy
10.2.4 Retinal Vein Occlusion
10.2.5 Others
10.3. Market Analysis – By End User
10.3.1 Hospital Pharmacy
10.3.2 Retail Pharmacy
10.3.3 Others
10.4. Market Analysis – By Country
10.4.1 GCC
10.4.2 South Africa
10.4.3 Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Competition Dashboard
11.4. Comparative Analysis –Major Players
11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))
11.5.1 Merck& Co., Inc.
11.5.2 Novartis AG
11.5.3 Allergan plc
11.5.4 Regeneron Pharmaceuticals, Inc.
11.5.5 Santen Pharmaceutical Co., Ltd.
11.5.6 F.Hoffmann-La Roche AG
12. Strategic Recommendations
Related Reports